YUBIOLOGICS, 26.86% ↑ on COVID-19 (Diagnosis/Treatment/Vaccine Development) Theme Uptrend

On the 18th, the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme rose by 3.09% compared to the previous day, showing strength, while YuvioLogics, a related stock drawing attention, surged by 26.86% compared to the previous day. YuvioLogics is known as a research and development company of biological preparations and pharmaceuticals.

[Graph] Major stock price changes in the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme



According to the analysis by Thinkpool RoboAlgorithm RASSI, YuvioLogics’ quant financial score is 45.76 points, which is higher in growth and profitability scores than the average of other stocks related to the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme, ranking 11th within the theme. This indicates that compared to other stocks in the theme, YuvioLogics has a relatively fast increase in sales and net profit, and also shows good efficiency in profit generation.

[Table] Top financial scores within the theme


※ The quant financial score is the result of RoboAlgorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.